Sai Parenterals Ltd

AI

Sai Parenterals Ltd

₹ 495 -1.27%
19 Nov - close price
About

Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.[1]

Key Points

Business Profile[1][2]
Sai Parenteral is a diversified pharmaceutical formulations company engaged in R&D, manufacturing, and commercialization of products across both domestic and international markets. Over time, the company has evolved from being a parenteral-focused player into a full-fledged diversified formulations platform, significantly reducing its dependency on injectables in the process.

  • Market Cap ₹ 2,189 Cr.
  • Current Price ₹ 495
  • High / Low ₹ 706 / 400
  • Stock P/E 87.8
  • Book Value ₹ 112
  • Dividend Yield 0.00 %
  • ROCE 5.28 %
  • ROE 4.88 %
  • Face Value ₹ 5.00

Pros

  • Debtor days have improved from 253 to 173 days.

Cons

  • Stock is trading at 4.41 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has low interest coverage ratio.
  • Tax rate seems low
  • Company has a low return on equity of 8.64% over last 3 years.
  • Company has high debtors of 173 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
33 54 96 198 179 195
29 42 100 172 155 155
Operating Profit 5 11 -4 26 24 40
OPM % 14% 21% -3.7% 13% 13% 21%
1 1 3 3 4 4
Interest 2 2 5 8 9 9
Depreciation 1 1 6 8 8 25
Profit before tax 2 9 -12 12 10 10
Tax % 30% 31% -43% -6% 19% -6%
1 6 -7 13 8 11
EPS in Rs 0.38 1.72 -1.80 2.98 1.79 2.38
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
97 154 163 381 668
78 122 124 342 581
Operating Profit 19 32 39 39 86
OPM % 19% 21% 24% 10% 13%
0 1 1 9 13
Interest 6 11 12 19 32
Depreciation 6 9 8 17 47
Profit before tax 7 13 20 12 20
Tax % 40% 33% 28% -20%
4 8 14 14 25
EPS in Rs 1.19 2.28 3.92 3.23 5.35
Dividend Payout % 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 58%
TTM: 134%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 48%
TTM: -1%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 9%
Last Year: 5%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 7 13 13 22 312
Reserves 24 61 80 469 184
69 119 94 469 374
34 75 85 465 450
Total Liabilities 134 268 272 1,424 1,320
44 70 53 364 377
CWIP 2 0 0 212 269
Investments 0 0 0 0 0
88 198 219 848 674
Total Assets 134 268 272 1,424 1,320

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026
-13 -30 33 93
-19 -46 0 -274
24 79 -36 596
Net Cash Flow -8 2 -2 415
Free Cash Flow -30 -72 41 -184
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit -54% -94% 86% 253%

Ratios

Consolidated / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 231 302 283 173
Inventory Days 83 143 199 259
Days Payable 140 203 225 224
Cash Conversion Cycle 174 242 256 208
Working Capital Days 19 72 79 -161
ROCE % 16% 17% 5%

Insights

In beta
Mar 2023 Mar 2024 Mar 2025 Mar 2026
Group-wide capacity utilisation
%

Log in to view insights

Please log in to see hidden values.

Login
Cumulative product registrations in regulated markets
count
Dossiers approved/filed in the year
count
Dossiers developed in-house by R&D subsidiary (cumulative)
count
Dossiers under development (pipeline)
count
Group installed manufacturing capacity
million units
Number of complex products in portfolio
count
Pharmacy reach in Australia via long-term supply networks
count
Share of consolidated revenue from long-term supply contracts in regulated markets
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Mar 2026Jun 2026Sep 2026
51.16% 51.16% 51.16%
5.73% 4.03% 2.85%
12.86% 8.52% 7.83%
30.25% 36.29% 38.16%
No. of Shareholders 7,6879,31213,645

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents